Ovid Therapeutics vs Cartesian Therapeutics
Ovid Therapeutics is the larger business, with $7.3m of revenue in fiscal 2025 against $2.8m for Cartesian Therapeutics (2.6 times as much). Ovid Therapeutics grew faster (1181.3% against -92.8%). Ovid Therapeutics kept more of each dollar of sales as profit: a net margin of -240.1% against -4658.6%.
| Latest fiscal year | Ovid TherapeuticsOVID, 2025 | Cartesian TherapeuticsRNAC, 2025 |
|---|---|---|
| Revenue | $7.3m | $2.8m |
| Revenue growth | 1181.3% | -92.8% |
| Net income | −$17.4m | −$130m |
| Operating margin | -585.2% | -5127.1% |
| Net margin | -240.1% | -4658.6% |
| Return on equity | -17.5% | — |
| Free cash flow | −$38.3m | −$79.4m |
| Cash | $13.2m | $125m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | 75 |
| Market value | $446m | $193m |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 2 sales | 1 buys, 3 sales |